Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. (Nasdaq: CLOV) is a physician enablement technology company and Medicare Advantage insurer whose activities generate frequent news across healthcare, technology, and capital markets. The company focuses on Medicare Advantage PPO and HMO plans in several states and uses its Clover Assistant platform to support clinical decision-making and chronic disease management for people on Medicare.
News about Clover Health often centers on membership growth and plan performance in Medicare Advantage, including updates on enrollment during the Annual Enrollment Period, changes in plan offerings, and the design of affordable, high-choice PPO products. Company announcements also highlight clinical quality achievements, such as HEDIS performance and CMS Star Ratings for its PPO and HMO plans, which influence future payment years and are important to investors and healthcare partners.
Because Clover Health combines insurance operations with a technology platform, its news flow includes technology and data-driven care developments. This can involve new research and whitepapers from its subsidiary Counterpart Health on the impact of Counterpart Assistant, evidence on earlier diagnosis and reduced hospitalizations for chronic diseases, and platform enhancements such as ambient scribing, natural language chat, and enterprise-level tools for value-based care.
Investors and industry observers can also expect earnings releases, financial guidance updates, and SEC-related communications, including Form 8-K filings tied to quarterly results, responses to shareholder questions, and commentary on CMS rate and Star Rating changes. In addition, Clover Health periodically announces participation in major healthcare investor conferences and changes in its board of directors or governance structure.
This news page aggregates these developments in one place, allowing readers to follow Clover Health’s progress in Medicare Advantage, its technology initiatives through Clover Assistant and Counterpart Health, and its ongoing financial and regulatory disclosures over time.
Clover Health (Nasdaq: CLOV) announced that Peter Kuipers stepped down as Chief Financial Officer effective March 30, 2026, remaining as an advisor through April 24, 2026. The board named Clay Thornton, divisional CFO of the company's insurance plan, as Interim CFO effective immediately. The company reiterated its most recently issued full fiscal year 2026 financial guidance, previously updated on February 26, 2026.
This leadership change emphasizes continuity by promoting an internal finance leader with Medicare Advantage experience while the company maintains its prior guidance.
Counterpart Health (Nasdaq: CLOV) released a whitepaper showing use of Counterpart Assistant (CA) clinical insights linked to higher flu vaccination rates and fewer flu-related acute care events among Medicare Advantage patients with chronic disease.
Key results: CA PCPs had 1.39x vaccination odds; provider completion of the flu insight raised odds to 1.89x. CA relationships correlated with 17% lower COPD acute-event incidence and 11% lower CHF incidence, plus 22% fewer COPD encounters and 18% fewer CHF encounters.
Clover Health (Nasdaq: CLOV) is live on Kno2 and participating in CMS-aligned interoperability initiatives, enabling real-time, patient-directed responses for clinical and claims data using FHIR (USCDI v3) standards.
Participation is powered by Counterpart Health infrastructure and Kno2 routing; live demonstrations will run March 10–12, 2026 at HIMSS 2026.
Clover Health (Nasdaq: CLOV) announced it is the first payer live on a CMS Aligned Network and TEFCA for patient-directed requests, enabling real-time responses to clinical and claims data in standardized FHIR (USCDI v3) formats. Counterpart Health powers the underlying infrastructure and Kno2 routes secure requests across the network.
The milestone enables authenticated Medicare members to request and receive structured clinical and claims data in real time, and Clover, Kno2, and Counterpart will demonstrate an end-to-end response at HIMSS 2026, March 10–12 at Kno2 booth #12720.
Clover Health (Nasdaq: CLOV) reported full year 2025 results and provided 2026 guidance. Key 2025 results: $1.924B total revenues (+40% YoY), Medicare Advantage membership 113,803 (+38% YoY), GAAP net loss $85.5M, and Adjusted EBITDA $21.7M. For 2026 the company guides 154,000–158,000 average MA members, total revenues of $2.81B–$2.92B, Consolidated Gross profit $470M–$510M, Adjusted EBITDA $50M–$70M, and GAAP Net Income $0M–$20M.
Management cited improving cohort economics, Clover Assistant-driven care, and membership scaling as drivers toward first full-year GAAP profitability in 2026.
Clover Health (Nasdaq: CLOV) said CFO Peter Kuipers will present at the Leerink 2026 Global Healthcare Conference on March 10, 2026 at 9:20 a.m. ET.
A live webcast and replay of the presentation and Q&A will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) will report its fourth quarter and full year 2025 financial results after market close on Thursday, February 26, 2026, and host a webcast at 5:00 p.m. Eastern Time.
The webcast will be available live and archived for 12 months on Clover Health investor relations, and registration is available via the provided webcast link.
Clover Health (Nasdaq: CLOV) reported a 53% year-over-year increase in Medicare Advantage PPO membership for the 2026 plan year, entering 2026 with ~153,000 members. The company said >95% AEP retention and that >97% of members are in its flagship PPO, which it ranks #1 nationally on core HEDIS metrics. Clover expects to achieve its first full-year GAAP net income profitability in 2026, citing improving cohort economics, SG&A leverage, a 4.0 Star payment impact, and a favorable 2026 CMS rate update.
Counterpart Health (CLOV) reported 2025 highlights showing scaled clinical impact from its AI physician‑enablement platform, Counterpart Assistant (CA). Key outcomes include a >450% YoY increase in live third‑party customer clinicians, an approximate 1,500 basis point MCR differential for returning Clover members with CA PCPs, and the PPO Medicare Advantage plan achieving the #1 HEDIS score nationwide for a second year.
Retrospective analyses found earlier COPD diagnosis (new members 75% more likely in year one), higher outpatient pulmonology use (+18%), lower all‑cause hospitalizations (CHF −18%; COPD −15%), reduced 30‑day readmissions (CHF −25%; COPD −18%), and 70–89% higher diagnosis rates in high ADI neighborhoods. Product expansions included integrated ambient scribing, natural language chat, proactive visit summaries, and broader enterprise capabilities.
Clover Health (Nasdaq: CLOV) said its CEO Andrew Toy will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 11:15 a.m. ET.
A live webcast and a replay of the presentation and Q&A will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.